2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.41 Real-World Intracranial and Extracranial Efficacy Plus Safety Analysis of Tarlatamab in Extensive-Stage Small Cell Lung Cancer

PP01.41 Real-World Intracranial and Extracranial Efficacy Plus Safety Analysis of Tarlatamab in Extensive-Stage Small Cell Lung Cancer

Back to course

Pdf Summary

The study titled "PP-01.41: Real-World Intracranial and Extracranial Efficacy Plus Safety Analysis of Tarlatamab in Patients with Extensive-Stage Small Cell Lung Cancer" focuses on the efficacy and safety of Tarlatamab, a bispecific T cell engager therapy targeting Delta-Like Ligand 3, which was approved by the FDA in May 2024 for relapsed extensive-stage small cell lung cancer (ES-SCLC). The study was conducted at the MD Anderson Cancer Center and analyzed data from 31 patients treated with Tarlatamab.<br /><br />Key findings include promising efficacy data, especially in patients with untreated intracranial metastases. Systemic responses showed that 59% experienced tumor shrinkage, while 29% had tumor growth. Intracranial responses were positive, with 82% showing tumor shrinkage for those with untreated brain metastases. However, adverse events were of concern; higher rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were observed compared to clinical trials. <br /><br />Of the 31 patient cohort, 39% exhibited CRS, and 13% showed grade 3 or more ICANS, requiring variations in management strategies. These adverse events occasionally necessitated intensive care unit (ICU) stays.<br /><br />Demographic data indicated an average age of 66 years, with a diverse patient group predominantly from Texas. The cohort had various baseline characteristics, including previous lines of therapy and the presence of brain metastases.<br /><br />The study concludes that while Tarlatamab demonstrates promising therapeutic benefits, careful monitoring and management of its unique toxicities are essential. Continuing data collection aims to further understand the safety and effectiveness of Tarlatamab in real-world settings. Further research and adaptation of management protocols may enhance patient outcomes, especially concerning its rapid adoption in broader clinical practices.

Asset Subtitle

Mitchell Parma

Keywords

Tarlatamab

small cell lung cancer

Delta-Like Ligand 3

intracranial efficacy

extracranial efficacy

cytokine release syndrome

immune effector cell-associated neurotoxicity syndrome

tumor shrinkage

real-world study

adverse events